Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
OPERATING EXPENSES:
Research and development	$ 19,818	$ 15,920	$ 38,853	$ 31,282
General and administrative	12,846	11,336	25,599	21,394
Total operating expenses	32,664	27,256	64,452	52,676
LOSS FROM OPERATIONS:	(32,664)	(27,256)	(64,452)	(52,676)
OTHER INCOME, NET:
Other income, net	627	240	1,336	374
Foreign exchange gains	1,376	1,958	4,061	3,291
Benefit from R&D tax credit	2,520	4,077	6,836	6,999
Total other income, net	4,523	6,275	12,233	10,664
Loss before income taxes	(28,141)	(20,981)	(52,219)	(42,012)
Income tax expense	(194)	(56)	(324)	(196)
Net loss	(28,335)	(21,037)	(52,543)	(42,208)
Other comprehensive (loss) income:
Foreign exchange translation adjustment	717	(17,134)	139	(24,327)
Comprehensive loss	$ (27,618)	$ (38,171)	$ (52,404)	$ (66,535)
Net loss per share attributable to ordinary shareholders - basic (in dollars per share)	$ (0.62)	$ (0.50)	$ (1.19)	$ (1.00)
Net loss per share attributable to ordinary shareholders - diluted (in dollars per share)	$ (0.62)	$ (0.50)	$ (1.19)	$ (1.00)
Weighted average ordinary shares outstanding - basic (in shares)	45,565,991	42,474,987	44,153,772	42,110,161
Weighted average ordinary shares outstanding - diluted (in shares)	45,565,991	42,474,987	44,153,772	42,110,161